August Troendle Biography: Net Worth, Religion, Age, Medpace, Height, Ethnicity, Wife, Businesses
August James Troendle, widely recognized as August Troendle, is an American physician, entrepreneur and healthcare executive best known as the founder, chief executive officer and chairman of Medpace Holdings, a global contract research organization specializing in clinical development services for pharmaceutical, biotechnology and medical-device companies.
He built Medpace after gaining experience with the U.S. Food and Drug Administration and Sandoz, combining medical expertise with business leadership to establish the company as a major participant in the clinical research industry.
Trending Now!!:
| August Troendle | |
|---|---|
|
|
| Wiki Facts & About Data | |
| Real Name: | August James Troendle |
| Stage Name: | August Troendle |
| Born: | 1956 (age 70 years old) |
| Place of Birth: | United States |
| Nationality: | American |
| Ethnicity: | White American |
| Religion: | Christianity |
| Parents: | Mr and Mrs. Troendle |
| Relationship: | Susan E. Burwig |
| Occupation: | Physician, Entrepreneur, Healthcare Executive, Businessman |
| Net Worth: | $4.3 billion |
Early Life and Education
August Troendle was born in 1956 in the United States.
He was raised by Mr and Mrs. Troendle and later pursued a medical career, establishing the educational foundation that would lead him into drug development and clinical research. Details concerning his siblings have not been publicly disclosed.
After completing his undergraduate education, August earned his Medical Degree from the University of Maryland School of Medicine and later obtained a Master of Business Administration from Boston University.
His medical training was followed by regulatory and pharmaceutical experience, including work at the U.S. Food and Drug Administration and Sandoz, where he focused on the clinical development of lipid-altering medicines. His background is White American and his religious tradition is Christianity.
Career
August Troendle began his professional medical and pharmaceutical career at the U.S. Food and Drug Administration, working from 1986 to 1987 as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products.
He then joined Sandoz, where he held progressively senior responsibilities between 1987 and 1992 and worked on the clinical development of lipid-altering agents.
His combined experience in medicine, pharmaceutical development and regulatory affairs provided the foundation for his move into healthcare entrepreneurship.
In July 1992, Troendle founded Medpace in Cincinnati, Ohio, and led its transformation from a small clinical research operation into an international contract research organization serving pharmaceutical, biotechnology and medical-device companies.
He has served as Medpace’s chief executive officer and chairman of the board since its founding and was also president until July 2021.
Beyond Medpace, he has served as a director of several healthcare and biotechnology companies, including Coherus BioSciences, Xenon Pharmaceuticals, LIB Therapeutics, CinCor Pharma and CinRx Pharma.
His leadership and substantial ownership of Medpace have made him one of the most prominent figures in the clinical research industry.
Personal Life
August Troendle, 70 years old, has maintained a grounded personal life outside his business activities.
He has not publicly established a marriage or spouse, while Susan E. Burwig, Medpace’s executive vice president of operations, is identified as the person with whom he cohabitates; the two have been associated personally and professionally for many years.
No children have been disclosed in his public record, and Troendle has generally kept family matters away from the public sphere.
Net Worth
August Troendle has an estimated net worth of $4.3 billion. His fortune is derived principally from his substantial ownership of Medpace Holdings, the clinical research company he founded in 1992, together with executive compensation and related investments.
His beneficial ownership of Medpace has remained substantial, with his holdings representing approximately 19% of the company’s outstanding shares at the end of 2025.
What People Ask
NOTICE!! NOTICE!! NOTICE!!
At TheCityCeleb, we strive to provide accurate and up-to-date biographies and entertainment news, focusing on celebrities. Our editorial team researches information from reputable sources, including interviews, official statements, and verified media.If you spot an error or have additional details, please contact us at editor@thecityceleb.com. We value your feedback and are committed to maintaining trustworthy content.
